Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy
ObjectiveTo analyze the proportion and clinicopathological characteristics of HER2-positive breast cancer patients with BRCA1/2 pathogenic variants, and their response to neoadjuvant anti-HER2 targeted therapy. MethodsThe clinicopathological data of 531 breast cancer patients with germline BRCA1/2 p...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2025-06-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.25.0101 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849418602143285248 |
|---|---|
| author | Xingyu LIAO Huimin LIU Jie SUN Li HU Juan ZHANG Lu YAO Ye XU Yuntao XIE |
| author_facet | Xingyu LIAO Huimin LIU Jie SUN Li HU Juan ZHANG Lu YAO Ye XU Yuntao XIE |
| author_sort | Xingyu LIAO |
| collection | DOAJ |
| description | ObjectiveTo analyze the proportion and clinicopathological characteristics of HER2-positive breast cancer patients with BRCA1/2 pathogenic variants, and their response to neoadjuvant anti-HER2 targeted therapy. MethodsThe clinicopathological data of 531 breast cancer patients with germline BRCA1/2 pathogenic variants (201 with BRCA1 variants and 330 with BRCA2 variants) were analyzed. ResultsAmong the 201 BRCA1 and 330 BRCA2 variants, 17 (8.5%) and 42 (12.7%) HER2-positive breast cancer cases were identified, respectively, accounting for 11.1% of all BRCA1/2-mutated breast cancers. Compared with BRCA1/2-mutated HR-positive/HER2-negative patients, HER2-positive patients did not present any significant differences in clinicopathological features; however, compared with triple-negative breast cancer patients, HER2-positive patients had a later onset age and lower tumor grade. Among the 17 patients who received neoadjuvant anti-HER2 targeted therapy, 10 cases achieved pCR (58.8%), whereas 7 cases did not (41.2%). ConclusionHER2-positive breast cancer accounts for more than 10% of BRCA1/2-mutated patients. Approximately 40% of these patients fail to achieve pCR after neoadjuvant targeted therapy. This phenomenon highlights the possibility of combining anti-HER2 targeted agents with poly (adenosine diphosphate-ribose) polymerase inhibitors. |
| format | Article |
| id | doaj-art-2444dfc4fc284b21b0df41d1be31ec55 |
| institution | Kabale University |
| issn | 1000-8578 |
| language | zho |
| publishDate | 2025-06-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj-art-2444dfc4fc284b21b0df41d1be31ec552025-08-20T03:32:24ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782025-06-0152649149510.3971/j.issn.1000-8578.2025.25.010120250101Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted TherapyXingyu LIAO0Huimin LIU1Jie SUN2Li HU3Juan ZHANG4Lu YAO5Ye XU6Yuntao XIE7Familial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaFamilial & Hereditary Cancer Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, ChinaObjectiveTo analyze the proportion and clinicopathological characteristics of HER2-positive breast cancer patients with BRCA1/2 pathogenic variants, and their response to neoadjuvant anti-HER2 targeted therapy. MethodsThe clinicopathological data of 531 breast cancer patients with germline BRCA1/2 pathogenic variants (201 with BRCA1 variants and 330 with BRCA2 variants) were analyzed. ResultsAmong the 201 BRCA1 and 330 BRCA2 variants, 17 (8.5%) and 42 (12.7%) HER2-positive breast cancer cases were identified, respectively, accounting for 11.1% of all BRCA1/2-mutated breast cancers. Compared with BRCA1/2-mutated HR-positive/HER2-negative patients, HER2-positive patients did not present any significant differences in clinicopathological features; however, compared with triple-negative breast cancer patients, HER2-positive patients had a later onset age and lower tumor grade. Among the 17 patients who received neoadjuvant anti-HER2 targeted therapy, 10 cases achieved pCR (58.8%), whereas 7 cases did not (41.2%). ConclusionHER2-positive breast cancer accounts for more than 10% of BRCA1/2-mutated patients. Approximately 40% of these patients fail to achieve pCR after neoadjuvant targeted therapy. This phenomenon highlights the possibility of combining anti-HER2 targeted agents with poly (adenosine diphosphate-ribose) polymerase inhibitors.http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.25.0101brca1/2 pathogenic varianther2-positive breast cancerclinicopathological characteristicneoadjuvant therapy |
| spellingShingle | Xingyu LIAO Huimin LIU Jie SUN Li HU Juan ZHANG Lu YAO Ye XU Yuntao XIE Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy Zhongliu Fangzhi Yanjiu brca1/2 pathogenic variant her2-positive breast cancer clinicopathological characteristic neoadjuvant therapy |
| title | Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy |
| title_full | Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy |
| title_fullStr | Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy |
| title_full_unstemmed | Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy |
| title_short | Clinicopathological Characteristics of HER2-Positive Breast Cancer Patients with BRCA1/2 Pathogenic Variants and Their Response to Neoadjuvant Targeted Therapy |
| title_sort | clinicopathological characteristics of her2 positive breast cancer patients with brca1 2 pathogenic variants and their response to neoadjuvant targeted therapy |
| topic | brca1/2 pathogenic variant her2-positive breast cancer clinicopathological characteristic neoadjuvant therapy |
| url | http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.25.0101 |
| work_keys_str_mv | AT xingyuliao clinicopathologicalcharacteristicsofher2positivebreastcancerpatientswithbrca12pathogenicvariantsandtheirresponsetoneoadjuvanttargetedtherapy AT huiminliu clinicopathologicalcharacteristicsofher2positivebreastcancerpatientswithbrca12pathogenicvariantsandtheirresponsetoneoadjuvanttargetedtherapy AT jiesun clinicopathologicalcharacteristicsofher2positivebreastcancerpatientswithbrca12pathogenicvariantsandtheirresponsetoneoadjuvanttargetedtherapy AT lihu clinicopathologicalcharacteristicsofher2positivebreastcancerpatientswithbrca12pathogenicvariantsandtheirresponsetoneoadjuvanttargetedtherapy AT juanzhang clinicopathologicalcharacteristicsofher2positivebreastcancerpatientswithbrca12pathogenicvariantsandtheirresponsetoneoadjuvanttargetedtherapy AT luyao clinicopathologicalcharacteristicsofher2positivebreastcancerpatientswithbrca12pathogenicvariantsandtheirresponsetoneoadjuvanttargetedtherapy AT yexu clinicopathologicalcharacteristicsofher2positivebreastcancerpatientswithbrca12pathogenicvariantsandtheirresponsetoneoadjuvanttargetedtherapy AT yuntaoxie clinicopathologicalcharacteristicsofher2positivebreastcancerpatientswithbrca12pathogenicvariantsandtheirresponsetoneoadjuvanttargetedtherapy |